Immune Correlates Analysis of the mRNA-1273 COVID-19 Vaccine Efficacy Trial

B. Gilbert, Peter; C. Montefiori, David; B. McDermott, Adrian; Fong, Youyi; Benkeser, David; Deng, Weiping; Zhou, Honghong; R. Houchens, Christopher; Martins, Karen; Jayashankar, Lakshmi; Castellino, Flora; Flach, Britta; C. Lin, Bob; O’Connell, Sarah; McDanal, Charlene; Eaton, Amanda; Sarzotti‐Kelsoe, Marcella; Lu, Yiwen; Yu, Chenchen; Borate, Bhavesh; W. P. van der Laan, Lars; S. Hejazi, Nima; Huynh, Chuong; M. Miller, Jacqueline; M. El Sahly, Hana; R. Baden, Lindsey; Baron, Mira; de la Cruz‐Merino, Luis; L. Gay, Cynthia; A. Kalams, Spyros; F. Kelley, Colleen; E Kutner, Mark; P. Andrasik, Michele; G. Kublin, James; Corey, Lawrence; M. Neuzil, Kathleen; N. Carpp, Lindsay; Pajón, Rolando; Follmann, Dean; O. Donis, Rubén; A. Koup, Richard

doi:10.1101/2021.08.09.21261290

Public

Immune Correlates Analysis of the mRNA-1273 COVID-19 Vaccine Efficacy Trial

Published in medRxiv • Aug 10, 2021

Authors:

Peter B. Gilbert

David C. Montefiori

Adrian B. McDermott

Abstract

BACKGROUND: In the Coronavirus Efficacy (COVE) trial, estimated mRNA-1273 vaccine efficacy against coronavirus disease-19 (COVID-19) was 94%. SARS-CoV-2 antibody measurements were assessed as correlates of COVID-19 risk and as correlates of protection. METHODS: Through case-cohort sampling, particip...

Subject

Medicine

Antibody

Serology

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!